Trial reportPeerJ2026
The effects of remimazolam on emergence agitation in patients undergoing nasal surgery: a clinical randomized controlled trial.
Trial report in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emergence Agitation (EA) is a common postoperative complication, particularly prevalent following nasal surgeries. The occurrence of EA not only elevates the risk of self-inflicted injuries or harm to others but may also lead to a series of severe postoperative complications. This study aims to evaluate the effect of remimazolam on EA in patients undergoing nasal surgery and compare its efficacy with that of conventional anesthetic agents. Materials and methods: This randomized controlled trial included 100 patients undergoing elective nasal surgery under general anesthesia from June to September 2024. Patients were randomly assigned (1:1) to the R group (remimazolam) or the C group (propofol). Agitation levels were measured using Riker Sedation-Agitation Scale (SAS), recording each patient's highest score. The primary outcome was the incidence of EA, with secondary outcomes including hemodynamic parameters, emergence time, and adverse events. Results: The results indicated that the incidence of EA was significantly lower in the R group compared to the C group (22% Conclusions: Remimazolam holds significant clinical application value and potential in surgeries with a high incidence of EA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.